517 related articles for article (PubMed ID: 24919951)
1. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
[TBL] [Abstract][Full Text] [Related]
2. Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
Bui QT; Im JH; Jeong SB; Kim YM; Lim SC; Kim B; Kang KW
Cancer Lett; 2017 Apr; 390():115-125. PubMed ID: 28108315
[TBL] [Abstract][Full Text] [Related]
3. Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
Simões BM; O'Brien CS; Eyre R; Silva A; Yu L; Sarmiento-Castro A; Alférez DG; Spence K; Santiago-Gómez A; Chemi F; Acar A; Gandhi A; Howell A; Brennan K; Rydén L; Catalano S; Andó S; Gee J; Ucar A; Sims AH; Marangoni E; Farnie G; Landberg G; Howell SJ; Clarke RB
Cell Rep; 2015 Sep; 12(12):1968-77. PubMed ID: 26387946
[TBL] [Abstract][Full Text] [Related]
4. Biological and clinical implications of nicastrin expression in invasive breast cancer.
Filipović A; Gronau JH; Green AR; Wang J; Vallath S; Shao D; Rasul S; Ellis IO; Yagüe E; Sturge J; Coombes RC
Breast Cancer Res Treat; 2011 Jan; 125(1):43-53. PubMed ID: 20224929
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
6. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.
Clementz AG; Rogowski A; Pandya K; Miele L; Osipo C
Breast Cancer Res; 2011 Jun; 13(3):R63. PubMed ID: 21679465
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
8. Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo.
Lombardo Y; Filipović A; Molyneux G; Periyasamy M; Giamas G; Hu Y; Trivedi PS; Wang J; Yagüe E; Michel L; Coombes RC
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16558-63. PubMed ID: 23012411
[TBL] [Abstract][Full Text] [Related]
9. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
10. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
11. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches.
Rizzo P; Miao H; D'Souza G; Osipo C; Song LL; Yun J; Zhao H; Mascarenhas J; Wyatt D; Antico G; Hao L; Yao K; Rajan P; Hicks C; Siziopikou K; Selvaggi S; Bashir A; Bhandari D; Marchese A; Lendahl U; Qin JZ; Tonetti DA; Albain K; Nickoloff BJ; Miele L
Cancer Res; 2008 Jul; 68(13):5226-35. PubMed ID: 18593923
[TBL] [Abstract][Full Text] [Related]
12. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells.
Lee J; Sehrawat A; Singh SV
Breast Cancer Res Treat; 2012 Nov; 136(1):45-56. PubMed ID: 22965833
[TBL] [Abstract][Full Text] [Related]
13. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.
Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ
Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
Wang Z; Li Y; Kong D; Banerjee S; Ahmad A; Azmi AS; Ali S; Abbruzzese JL; Gallick GE; Sarkar FH
Cancer Res; 2009 Mar; 69(6):2400-7. PubMed ID: 19276344
[TBL] [Abstract][Full Text] [Related]
15. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
Wang L; Dai G; Yang J; Wu W; Zhang W
Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
[TBL] [Abstract][Full Text] [Related]
16. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
17. DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation.
Faronato M; Nguyen VT; Patten DK; Lombardo Y; Steel JH; Patel N; Woodley L; Shousha S; Pruneri G; Coombes RC; Magnani L
Oncotarget; 2015 Sep; 6(26):22467-79. PubMed ID: 26093085
[TBL] [Abstract][Full Text] [Related]
18. Differential patterns of NOTCH1-4 receptor expression are markers of glioma cell differentiation.
Dell'albani P; Rodolico M; Pellitteri R; Tricarichi E; Torrisi SA; D'Antoni S; Zappia M; Albanese V; Caltabiano R; Platania N; Aronica E; Catania MV
Neuro Oncol; 2014 Jan; 16(2):204-16. PubMed ID: 24305720
[TBL] [Abstract][Full Text] [Related]
19. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
20. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
